drugset / Trial / NCT04730349
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children, adolescents and young adults with recurrent or treatment-resistant cancer.
Timeline
- Start
- 2021-06-03
- Primary completion
- 2022-06-22
- Completion
- 2022-06-22
Outcome
Outcome not reported
Stopped (Business): “Business objectives have changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bempegaldesleukin | Protein / enzyme biologic | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |